Brutons Tyrosine Kinase (BTK) Inhibitors Pipeline Insight Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Brutons Tyrosine Kinase (BTK) Inhibitors – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This Brutons Tyrosine Kinase (BTK) Inhibitors – Pipeline Insight, 2021 report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Brutons Tyrosine Kinase (BTK) Inhibitors – Pipeline Insight, 2021” outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.
The assessment part of the report embraces, in depth Brutons Tyrosine Kinase (BTK) Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brutons Tyrosine Kinase (BTK) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Brutons Tyrosine Kinase (BTK) Inhibitors drugs?
- How many Brutons Tyrosine Kinase (BTK) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brutons Tyrosine Kinase (BTK) Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brutons Tyrosine Kinase (BTK) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Brutons Tyrosine Kinase (BTK) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- InnoCare Pharma
- BeiGene
- Principia Biopharma
- Carna Biosciences
- Loxo Oncology
- Aptose Biosciences
- Biogen
Key Products
- Orelabrutinib
- Zanubrutinib
- PRN473
- Rilzabrutinib
- AS-0871
- AS-1763
- Pirtobrutinib
- CG-806
- BIIB091
Key Topics Covered:
Introduction
Executive Summary
Brutons Tyrosine Kinase (BTK) Inhibitors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Rilzabrutinib: Principia Biopharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Orelabrutinib: InnoCare Pharma
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
PRN473: Principia Biopharma
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Brutons Tyrosine Kinase (BTK) Inhibitors Key Companies
Brutons Tyrosine Kinase (BTK) Inhibitors Key Products
Brutons Tyrosine Kinase (BTK) Inhibitors- Unmet Needs
Brutons Tyrosine Kinase (BTK) Inhibitors- Market Drivers and Barriers
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/lupyu2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900